DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20211019

A retrospective study on pemetrexed induced nephrotoxicity in non-small cell lung carcinoma patients

Sharat Venkat Reddy Kallem, Punukula Harichandana, C. Bhavya, Narender Kumar Thota

Abstract


Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent that has been shown to have broad-spectrum efficacy in a variety of human cancers, including NSCLC and mesothelioma. Dose-limiting hematologic toxicities are among the most serious side effects. PEM nephrotoxicity is well-known, but its occurrence is thought to be rare. Aim was to determine nephrotoxicity induced due to pemetrexed in non-small cell lung cancer patients.

Methods: In patients with the NSCLC, we record a retrospective review on PEM- induced renal toxicity. A total of 327 NSCLC patients were treated in our hospital between 2012 and 2019. Of these, 134 patients were diagnosed with 2 or more chemotherapy cycles. 60 of these patients have been diagnosed with combination of antineoplastic drugs based on pemetrexed and platinum. Others were removed from the study and were also required to be tested for other potential causes of renal injury.

Results: Suitable statistical tools were used and data was analysed which showed that repeated chemo cycles of pemetrexed leads to the reversible acute kidney injury. With the results from our study we can understand the severity of nephrotoxicity induced with pemetrexed in patients with non-small cell lung cancer. Most of the patients were in the first and second stages of nephrotoxicity and most of them were male. Majority of the patients were also above 40 years of age and also endured more than 4 chemo cycles.

Conclusions: It shows that PEM allows longer survival, but acute or chronic kidney failure is the price for this achievement. In conclusion, renal toxicity should be controlled routinely in patients treated with pemetrexed. Before each cycle of pemetrexed, creatinine clearance should be measured. Patients need to be well hydrated during treatment. The patient should also be tested for concomitant medications, and any nephrotoxic symptoms should be reviewed and those drugs removed.


Keywords


Acute kidney injury, GFR, Non-small cell lung cancer, Pemetrexed

Full Text:

PDF

References


Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 2009;374(9699):1432-40.

Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895-902.

Adjei AA. (2004). Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5:S51-5.

Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy. 2006;26(5):641-54.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552-62.

Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, et al. (2007). Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13(9):2675-83.

Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta®). Oncologist. 2004;9(5):482-8.

Sbitti Y, Chahdi H, Slimani K, Debbagh A, Mokhlis A, Albouzidi A, et al. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature. J Med Case Rep. 2017;11(1):1-3.

Zajjari Y, Azizi M, Sbitti Y, El Kabbaj D. (2017). Nephrotoxicity in a patient treated with pemetrexed. Indian J Nephrol. 2017;27(3).

Zattera T, Londrino F, Trezzi M, Palumbo R, Granata A, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol. 2017;6(2):43.

Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol. 2005;32:16-21.

Brandes JC, Grossman SA, Ahmad H. (2006). Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest. 2006;24(3):283-7.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. (2008). VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-36.

Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol. 2014;82(6):402-6.

Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;34(1):53-6.

Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219-27.

Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-α,-β, or-γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(4):607-15.

Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;34(1):53-56.

Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G. (2010). Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail. 2010;32(8):1000-4.

Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58(5):817-20.

Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol. 2014;82(6):402-6.